Status:
UNKNOWN
Sublingual Photobiomodulation in Parkinson's Disease
Lead Sponsor:
University of Nove de Julho
Conditions:
Parkinson Disease
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
This study evaluates the use of photobiomodulation in the treatment of patients with Parkinson's disease. Half of participants will receive treatment with low level laser therapy and exercises in comb...
Eligibility Criteria
Inclusion
- patients with Parkinson's disease diagnosed with the criteria of the UK Parkinsons' Disease Society Brain Bank Clinical Diagnostic Criteria
- In the stages I to III of the disease according to Hoehn \& Yahr's Parkinson's disease staging scale - modified;
- Individuals of both sexes,
- with more than 50 years
- who sign the informed consent form
Exclusion
- patients who present some adverse event during the development of the study,
- Who have another associated neurodegenerative disease,
- Have blood dyscrasia, HIV, heart failure, hepatic or renal insufficiency, infections, neoplasias, respiratory disorders, hypophysis and hypothalamus problems.
- Who fail to understand or perform procedures correctly because of physical and mental limitations.
Key Trial Info
Start Date :
September 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04028817
Start Date
September 10 2020
End Date
December 30 2021
Last Update
June 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daysi da Cruz Tobelem
São Paulo, Brazil, 04119010